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ABSTRACT
Preparation of Supramolecular Amphiphilic Cyclodextrin Bilayer Vesicles for
Pharmaceutical Applications
Kate E. Frischkorn

Recent pharmaceutical developments have investigated using supramolecular
nanoparticles in order to increase the bioavailability and solubility of drugs
delivered in various methods. Modification of the carbohydrate cyclodextrin
increases the ability to encapsulate hydrophobic pharmaceutical molecules by
forming a carrier with a hydrophobic core and hydrophilic exterior. Guest molecules
are commonly added to these inclusion complexes in order to add stability and
further increase targeting abilities of the carriers. One such guest molecule is
adamantine combined with a poly(ethylene glycol) chain. Vesicles are formed by
hydrating a thin film of amphiphilic cyclodextrin and guest molecules in buffer
solution that mimics physiological conditions. The solution is subject to freeze-thaw
cycles and extrusion, and the complexes are separated out via size exclusion
chromatography. Dynamic Light Scattering instrumentation is used to observe the
particle size distribution. Cargo release can be observed in fluorescent dye-loaded
vesicles by addition of a membrane-cleaving agent under a fluorimeter instrument.
Future work involving this drug delivery technology includes synthesizing a
chemically sensitive guest that will cleave in the presence of an intra-cellular antioxidant, and finally observing the uptake of these vesicles into live cells and testing
the delivery of cargo in vitro under physiological conditions.
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1. INTRODUCTION
1.1 Current Drug Delivery Methods
The pharmaceutical industry is one that is wildly diverse and rapidly expanding
due to emerging technologies and techniques. There have been countless drugs
and drug-related products since the beginning of mankind, ranging anywhere from
ancient holistic remedies to cutting-edge synthetically manufactured medications.
The wide range of variability of pharmaceutical products extends to their function
as well, treating mild headaches or a multitude of symptoms resulting from a
complex disease. As there are so many different kinds of drugs and ailments they
help treat, there is also a wide array of delivery methods. These methods are
determined by the pharmaceutical products’ specific molecular composition,
intended target inside the body, and dosage, to name a few factors. Some of the
most common drug delivery methods include oral dosage, parenteral, and
transdermal.1
While these methods of delivery make up a majority of drugs on the market
currently, there are several issues that could be improved upon. The main issue
with these methods is poor solubility and bioavailability. With about 85% of drugs
sold being orally administered (pills, capsules, gels, liquids, etc.), this affects a
large majority of the pharmaceutical industry.2 Less of the product reaches the
intended target if it is not readily bioavailable; higher concentrations of the product
are required during manufacturing in order to have the intended therapeutic
response. Another main issue with oral drugs is the harsh physiological conditions
they are exposed to throughout the digestive system.3 The drug must be able to
1

withstand harsh pH conditions and the lengthy journey to the small intestine, where
absorption occurs. For this reason, peptide or macromolecular drugs cannot be
administered orally. Parenteral drugs are able to administer the types of molecules
not compatible with oral dosage, but they are not as widely used. Due to the need
for trained professionals for administration, a decrease in patient compliance, and
higher pain that comes with injected medications, they are often more difficult to
produce. Transdermal deliveries offer a simple method of drug administration, but
they are not as efficient in systemic deliveries. The pharmaceutical product must
be able to pass through several layers of tissue in order to reach the bloodstream
and achieve systemic distribution.3
There are several methods that are being explored in order to improve the
bioavailability of pharmaceutical products. Due to the variation among the drugs’
unique chemistry and intended use, there is not a one-size-fits-all type of solution.
However, there have been recent advancements in using polymeric chemistry to
improve many aspects of the pharmaceutical industry.

1.2 Amphiphilic Polymers for Drug Delivery
Drug delivery systems incorporate both traditional delivery techniques with
newly engineered technologies.4 Polymers, with all their versatility and tailorability, are becoming more popular to include in pharmaceutical manufacturing.
Advancements in polymer chemistry in recent years have allowed more affordable
and efficient experimentation to alter pharmaceutical products.5 For example,
certain polymers can be added to oral dosage drugs in order to improve the taste,
2

and polymeric coatings can make swallowing easier. Targeting to a specific
location in the body can be done by including specific moieties to the formulation.
One such example is adding the protein transferrin (Tf) to a delivery system, as its
receptor (Tfr) is in higher abundance in tumor cells than healthy ones.12 This type
of targeting ensures that the drug delivery platform has a higher chance of
delivering anti-cancer drugs to the tumor site through receptor-mediated
endocytosis. Specific targeting in drug delivery systems can include more than just
ligand-receptor interactions.
Polymer drug delivery systems can be designed to be highly responsive to
the surrounding environment.6 Depending on the polymers used, delivery
platforms can be responsive to either chemical or physical stimuli. Chemical stimuli
include pH, ionic strength, or presence of particular molecules. Ester and acetal
groups are common functional groups that are pH sensitive, both of which can be
cleaved at high pH. Disulfide linkages are readily reduced by certain antioxidants
in high intracellular concentrations, such as cysteine or glutathione.7 These bonds
and functional groups can be included in drug delivery polymers as a way to
engineer controlled release of an encapsulated therapeutic agent. Figure 1, below,
shows examples of several compounds containing disulfide bonds. These can be
used to synthesize other polymeric molecules.

3

Figure 1. Examples of chemical structures containing disulfide linkages that are
redox-sensitive.

Exposures to temperature differences, ultrasound, or magnetic fields are
examples of physical stimuli. These physical triggers cause a change in the energy
of the polymer system, leading to conformational or solubility changes. An example
of a thermos-responsive polymer is PNIPAAm, which takes shape of a hydrophilic
coil below 32° C and collapses into a hydrophobic globule at higher temperatures
(Figure 2). Understanding the behavioral and chemical responses of polymers
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under certain physiological conditions allows for controlled targeting and release
of drug molecules.

Figure 2. Example of chemically (pH) or physically (temperature) responsive
polymer. Addition or removal of stimulus creates a reversible transition between
hydrophilic coils and hydrophobic globules.

Another polymeric method of improving efficiency of pharmaceuticals is the
use of dendrimers. These polymers are highly branched and spherically shaped.8
The center of the sphere is the initiating core, with layers of polymers growing
outwards in a 3D shape. Drugs can be loaded into the dendrimers in two different
ways as seen in Figure 3: either through van der Waals forces holding the drug
into the cavity between branches, or by including functionality on the surface that
will covalently bind with the drug. The surface layer of the dendrimer can include
different functional groups for specific targeting as well.9 The library of available
monomers that can be used to build a dendrimer drug carrier is near limitless, so
this method can be easily tailored to a particular drug or application for the desired
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delivery. Transdermal and oral dosage drugs are the most common administration
route of dendrimer carriers.10

Figure 3. Dendrimers as drug carriers. Drugs can be loaded into the open cavities
within the dendrimer (left) or covalently bonded to the surface layer (right).

1.3 Supramolecular Amphiphiles for Drug Delivery
A broader category of drug delivery is supramolecular nanoparticles. These
assemblies are in the nano-range, making them ideal for transportation through
tissue and cellular membranes.11 They are composed of several molecules selfassembled and stabilized by non-covalent interactions. In high enough
concentrations, they form 3D structures like micelles, bilayers, and vesicles.13
Hydrophobic and hydrophilic interactions most commonly cause these particular
assemblies to form, although electrostatic interactions are common as well. These
3D structures contain inner cavities that are capable of loading small molecules
into. Some of these containers can even load up to 20-30 wt.% into their cores.14
Lipids are gaining popularity in the drug carrier field due to their low toxicity
and ability to encapsulate hydrophobic, hydrophilic, and amphiphilic molecules.
6

Phospholipids fall in this category and are most well known for making up cellular
membranes. This membrane is composed of two layers of phospholipids held
together via hydrophobic-hydrophilic interactions. The hydrophilic heads of the
lipids face outwards on both sides, while the hydrophobic tails face inwards
towards each other. Due to the similar amphiphilic nature of both cell membranes
and supramolecular nanoparticles, these assemblies are being investigated as
potential drug carriers. Positively charged liposomes (vesicles made from lipids)
are being used to carry negatively charged siRNA for gene therapy.13 The mimicry
of the natural chemical structure of the cell membrane allows the nanocarrier to
pass through the membrane in order to deliver the drug cargo directly to its
intended target. Poly(ethylene glycol) (PEG) chains can easily be grafted onto
liposome surfaces to increase water solubility and reduce aggregation. In addition,
the hydroxyl groups on the end of the chains can be further modified for targeting
or controlled release, such as adding a ligand to target specific proteins.

Hydrophilic Chain

Cyclodextrin Core

Hydrophobic Chain

a) Micelle

b) Bilayer

c) Vesicle

Figure 4. 3D self-assemblies of amphiphilic supramolecular nanoparticles.
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Using these lipid systems as inspiration, polymers and other organic
molecules can be modified in order to have these hydrophobic-hydrophilic regions
to create 3D structures for drug delivery using supramolecular chemistry, shown
in Figure 4 above. One of the most used amphiphilic supramolecular nanoparticles
used for drug delivery is modified cyclodextrin.12

1.4 Amphiphilic Cyclodextrin Vesicles
1.4.1 Cyclodextrins
Cyclodextrins (CDs) are macrocyclic oligosaccharides composed of several
simple sugar molecules bonded together in a ring to form a truncated cone (Figure
6).5 Different types of CDs can be used, most commonly α-, β-, or γ-cyclodextrins
(having 6, 7, or 8 sugars, respectively (Figure 5)). The inside of the ring forms a
hydrophobic cavity, which is ideal for creating inclusion complexes with other
organic molecules, and the outer surface is hydrophilic.

Figure 5. Cyclodextrin, in which n = 6, 7, or 8 for α-, β-, or γ-CD, respectively.
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CDs gained popularity over 100 years ago with their discovery by Villiers
and Schardinger, but have only recently had potential pharmaceutical
applications.15 This time difference is due to recent advancements in
biotechnology that have allowed more cost-efficient mass production and
purification of cyclodextrins. With production costs much lower in recent years, the
use of CDs in pharmaceutical manufacturing has increased exponentially. These
molecules are in part attractive because of their inherently low toxicity levels, as
well as how bioavailable they are. The hollow cavity gives the opportunity to load
guest molecules through van der Waals forces.11 This allows for secure
encapsulation of either a drug or another type of guest molecule without covalent
bonds. CDs are not readily soluble in water, which is why modifications to the
hydroxyl groups are necessary to increase water solubility. Modifications that
create an amphiphilic structure also allow the CDs to self-assemble into bilayer
vesicles. These hollow spheres have an aqueous interior, which can encapsulate
small molecules.16

Figure 6. 3D configuration of β-cyclodextrin.

1.4.2 Amphiphilic Cyclodextrins
Bart Jan Ravoo, a professor at Universität Münster, has further progressed
the applications of CD vesicles in his work. The modifications that have improved
9

the potential to form these bilayers involve substituting a hydrophobic alkyl
thioether for a hydroxyl group on one side of the cyclodextrin.17 The α- and β-CDs
are better suited for pharmaceutical applications due to the fact that they are not
hydrolyzed by proteins in biologic fluids.15 β-CDs are used more than α-CDs
because their cavities are more voluminous and can therefore accommodate
larger guest molecules. The surface-to-volume ratio of β-CDs is attractive for
individualizing the molecules in order to demonstrate the desired characteristics,
such as charge, size, specific functional groups, or targeting proteins.12 A large
library of guest molecules that are compatible with CD cores is increased even
more when they are conjugated with other molecules to add additional desired
characteristics. Ravoo has made additional modifications to cyclodextrins to
increase water solubility: addition of hydrophilic molecule to hydroxyl groups on
the side of the CD opposite the hydrophobic thiol chains, as pictured in Figure 7.17
Hydrophilic poly(ethylene glycol) PEG chains were appended to the secondary
side of the CDs, thus making the CD amphiphilic. This increases solubility and selfassembly by sterically hindering CDs from aggregating and allowed neat bilayers
to form. Another advantage of using cyclodextrins as drug carriers is relatively
easy synthesis. No complicated or expensive reagents or techniques are used in
Ravoo’s procedures. This benefits pharmaceutical manufacturers by decreasing
cost of production and time required to synthesize these drug carriers, thus
increasing product output and marketability.

10

Figure 7. Amphiphilic β-CD modified with hydrophobic thioalkyl chain and
hydrophilic PEG chain.

Guest molecules used in inclusion complexes with cyclodextrins are most
commonly adamantane (Ad) derivatives due to a high binding affinity.12 These
guests aid in formation and stabilization of the vesicles. The round-shaped,
hydrophobic adamantane fits easily into the hydrophobic cavity within the
cyclodextrins and is stabilized by conformational changes and van der Waals
forces, shown below in Figure 8. Adamantane can be tacked on to a large variety
of polymeric molecules, depending on the desired functionality.

Figure 8. Adamantane (left) and cyclodextrin (middle) forming an inclusion
complex (right).

A very common polymer to use for the guest molecule is poly(ethylene
glycol) (PEG). This polymer is incredibly versatile, and when bonded with Ad, it
makes a guest molecule that increases water solubility and vesicle formation with
11

modified CDs. The end hydroxyl of the PEG chain can be further modified to tailor
to specific requirements. Biomarkers for targeting, radioactive molecules for
imaging, and large polymers to increase vesicle size are all examples of further
Ad-PEG guests.12,16 Ravoo creates a redox-responsive polymer shell attached to
vesicles formed by amphiphilic CDs through Ad-derivatives that form disulfide
bonds.18 This supramolecular nanoparticle is held together by including an
adamantane-derived guest molecule that connects the CD to the crosslinked
polymer shell. This shell contains disulfide bonds that are cleaved by glutathione
(GSH), an antioxidant naturally found in most living cells. It is a reducing agent that
breaks apart disulfide bonds in high enough concentrations, such as inside cells.
By using disulfide bonds to stabilize drug-carrying supramolecular nanoparticles,
cleavage of the disulfide bond causes the nano-assembly to fall apart and release
the

cargo

encapsulated

inside.

Intracellular

environments

have

higher

concentrations of GSH than extracellular matrices, so these inclusion complexes
can target load-release inside cells. Intracellular concentrations of GSH are
measured to be around 2-10 mM, while extracellular concentrations are much
smaller, at 2-20 μM.18
1.4.3 Characterization of Vesicles
Several methods are used to characterize the formation and properties of
vesicles.17,18,19 Scanning electron microscopy (SEM) and transition electron
microscopy (TEM) are methods in which to observe the surface structure of a
sample. They are similar in that they both use electrons to view, but SEM only
scans the surface with a beam of electrons while TEM transmits electrons through
12

a sample. Dynamic light scattering (DLS) uses lasers shining through a solution to
observe the particle size distributions within the sample.20 There are three different
methods to categorize the size distributions: intensity, volume, and number. The
intensity distribution measures how intense the reflected light is for each different
diameter detected. The volume distribution shows the percentage of total volume
taken up by each measured diameter particle. Used for the application of
cyclodextrin vesicles, the number intensity is measured, which measures what
fraction of the total number of particles a particular diameter is. Ravoo reported an
average range of 80-140 nm for vesicles formed by amphiphilic β-cyclodextrins.17
A simple way to determine successful encapsulation of hydrophilic molecules by
CD vesicles is addition of water-soluble carboxyfluorescein (CF) to the buffer
solution used to prepare vesicles.18 The CF is added at a self-quenching
concentration, so any dye encapsulated by the vesicles produces low fluorescent
measurements. Using a fluorimeter instrument, a small sample of vesicles is added
to excess buffer and the fluorescence is continuously measured. During the
measurement, a lysing agent can be added to the solution to force degradation of
the vesicles. A peak in fluorescence from the released CF, no longer at selfquenching concentration, is indicative of successful encapsulation.

1.5 Project Goals
The following report explores the preparation of bilayer vesicles made from
modified amphiphilic cyclodextrin with adamantane-derivative guest molecules. βcyclodextrin was solely used instead of α- or γ-cyclodextrins, due to the increased
13

applicability for pharmaceutical delivery. The only modification to these CDs is the
addition of an alkyl thioether on the primary side to make these host molecules
hydrophobic. Adamantane derived guest molecules were synthesized in order to
stabilize the vesicles in aqueous solutions and provide a hydrophilic region to drive
bilayer formation. Dynamic light scattering was used to observe the particle size
distribution to check for reported vesicle size range. Proper encapsulation was
tested for in a fluorimeter by lysing CF dye-loaded vesicles. The overall goal of this
project was to create bilayer vesicles using supramolecular chemistry between CD
containing hydrophobic chains and a hydrophilic adamantane-derived guest
molecule containing a redox-sensitive cleavable disulfide bond, depicted in Figure
9.

Figure 9. Project goal is to create bilayer vesicles through supramolecular
chemistry between hydrophobic modified CD (left) where n=10 or 12 and
hydrophilic guest containing a redox sensitive disulfide bond (right).

This method of vesicle formation is advantageous over Ravoo’s procedure
because it utilizes supramolecular chemistry. Ravoo’s modified CD were
amphiphilic by themselves, as there was a hydrophobic chain on the primary side
and hydrophilic chains on the secondary side. These modifications were enough
to drive hydrophobic/hydrophilic interactions to form bilayer membranes. However,
14

this project uses supramolecular interactions between hydrophobic hosts and
hydrophilic guests in order to create these bilayer vesicles. Modification of the
secondary side of CD is more difficult and time consuming than only modifying the
primary side, so CD used in this project are quicker and easier to synthesize. The
guest molecule is needed to form vesicles and are easy to couple several types of
end groups to. These guests are also targets for controlled release of cargo, as
they can be synthesized with easily breakable bonds that cause the degradation
of the bilayer membrane, as with a redox-sensitive disulfide linkage. This
schematic can be observed below in Figure 10.

Figure 10. Schematic of vesicle self-assembly and subsequent degradation and
release of cargo.
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2. EXPERIMENTAL METHODS
2.1 Material Synthesis
All commercial reagents were used as supplied unless otherwise stated. 1H
NMR spectra were recorded on a FT-NMR Bruker Avance 300 MHz BioSpin.
Vesicles were isolated in Dynamic light scattering experiments performed on a
Wyatt Technologies DynaPro NanoStar. Spectrofluorimeter Fluorescence
experiments were carried out using a Horiba Fluorolog equipped with an injection
port constructed in our lab from black cardboard. Extrusions were performed using
a mini-extruder purchased from Avanti Lipids using polycarbonate membranes
with 100 nm pore size. Dialysis was carried out using Float-A-Lyzer G2 dialysis
devices purchased from Spectrum.

Heptakis(6-bromo)- b-cyclodextrin

[1]
Stock b-cyclodextrin (b-CD) (4 g, 3.5 mmol) was dried by dissolving in
dimethylformamide (DMF) (~30 mL), then placed on rotary evaporation to remove
all solvent. Triphenylphosphene (PPh3) (18.4 g, 70 mmol), dissolved in DMF (~20
mL), and purged under nitrogen three times. Bromine (Br2) (11.2 g, 70 mmol) was
added drop-wise to PPh3 via syringe and stirred at 60° C for 30 minutes. The dried
b-CD in DMF (~20 mL) was added drop-wise. The reaction was stirred overnight
16

(~18 hours) at 80° C.

The reaction mixture was then placed under rotary

evaporation to reduce solvent to half volume, then added to ~ 150mL methanol
(MeOH). The pH was adjusted to 10-12 with potassium t-butoxide and stirred at
room temperature for 30 minutes. The reaction was added to ice water and
vacuum filtered over a frit. The precipitate was moved to a Falcon tube and
dissolved in MeOH. The sample was centrifuged three times in 5-minute intervals
at 7500 RPM. The MeOH was removed, and the precipitate was dissolved in DMF.
After rotary evaporation to remove all solvent, the product was dried under high
vacuum overnight (~12 hours) to obtain white powder. Figure 11 depicts the NMR
results obtained.

Heptakis(6-hexadecylthio)- b-cyclodextrin

[2]
Bromocyclodextrin (0.315 g, 0.2 mmol), dodecanethiol (0.488 g, 2.8 mmol),
and potassium t-butoxide (0.314 g, 2.8 mmol) were added to 50mL RBF with stir
bar and purged with nitrogen three times. Anhydrous DMF (~20 mL) was added
via syringe to cover the reaction, and stirred overnight (~18 hours) at 80° C. The
contents of the RBF were added to excess ice water and vacuum filtered over a
frit. The product was added to rapidly stirring MeOH (80 mL) at 50° C for an hour
to remove excess thiol. The solution was vacuum filtered again over a frit.

17

Precipitate was added to a 25mL RBF and dried completely under high vacuum
overnight (~12 hours) to obtain fluffy white powder.

Heptakis(6-decylthio)- b-cyclodextrin

[3]
Bromocyclodextrin (0.35 g, 0.22 mmol), decanethiol (0.542 g, 3.1 mmol),
and potassium t-butoxide (0.35 g, 3.1 mmol) were added to 50mL RBF with stir
bar and purged with nitrogen three times. Anhydrous DMF (~20 mL) was added
via syringe to cover reagents, and the reaction was allowed to stir overnight (~18
hours) at 80° C. The contents of the RBF were then added to excess ice water and
vacuum filtered over a frit. The product was added to rapidly stirring MeOH (80
mL) at 50° C for an hour to remove excess thiol. The solution was vacuum filtered
again over a frit. Precipitate was added to a 25mL RBF and dried completely under
high vacuum overnight (~12 hours) to obtain fluffy white powder.

Ad-PEG

[4]
18

Bromoadamantane (2 g, 9.3 mmol), tetra(ethylene glycol) (TEG) (10.8 g,
55.8 mmol), and triethylamine (2.73 g, 26.97 mmol) were added to 50mL RBF with
stir bar. Reaction stirred overnight (~18 hours) at 180° C, then allowed to cool to
room temperature. Dichloromethane (DCM) (~30 mL)

was added to the room

temperature mixture. In a separatory funnel, the solution was washed four times
with 2M HCl and once with brine. The organic layer was dried over MgSO4, and
the solvent was removed under reduce then placed under rotary evaporation until
a thick brown oil remained.
Ad-PEG

[5]
Bromoadamantane (2 g, 9.3 mmol), poly(ethylene glycol) with an average
molecular weight of 200 g/mol (PEG) (11.16 g, 55.8 mmol), and triethylamine (2.8
g, 27.9 mmol) were added to 50mL RBF with stir bar. Reaction stirred overnight
(~18 hours) at 180° C, then allowed to cool to room temperature. DCM (~30 mL)
was added to room temperature mixture. In a separatory funnel, solution was
washed four times with 2M HCl and once with brine. Organic layer was further
dried over MgSO4, then placed under rotary evaporation until a thick brown oil
remained.

19

Ad-SS-PEG

[7]

[6]

PEG (3 g, 15 mmol), dithiodipropionoic acid (9.46 g, 45 mmol), and
dimethylaminopyridine (DMAP) (0.55 g, 4.5 mmol) were added to 100mL RBF with
stir bar and purged with nitrogen three times. Anhydrous DCM was added via
syringe to cover reaction (~25mL) and stirred in ice bath until it reached 0° C.
Dicyclohexylcarbodiimide (DCC) (3.4 g, 16.5 mmol) was dissolved in 5mL DCM
and added to reaction drop-wise via syringe. Reaction was stirred at 0° C for one
hour, then warmed to room temperature and stirred overnight (~20 hours).
Contents of RBF were added to separatory funnel with deionized water (~25 mL),
and DCM was removed. Keeping the aqueous layer, the solution was washed
twice with DCM. The aqueous layer was placed under rotary evaporation to
remove water. The film was rehydrated with nanopure (Milli-Q, 18 MΩ) water and
placed in dialysis membrane. The membrane was placed in a large beaker of
nanopure water and gently stirred overnight (~20 hours) at room temperature. The
contents of the dialysis membrane were added to small Falcon tubes and frozen
under liquid nitrogen. The water was removed from the product [6] under a
lyophilizer overnight (~18 hours).
PEG-SS [6] (from pervious procedure) (0.183 g, 0.466 mmol), Adamantanol
(0.71 g, 4.66 mmol) and DMAP (0.028 g, 0.233 mmol) were added to 250 mL RBF
with stir bar. The flask was sealed and purged with nitrogen three times. Anhydrous
DCM was added via syringe to cover reaction, ~25mL. Reaction was stirred over
20

ice bath to reach 0° C. DCC (0.29 g, 1.4 mmol) was dissolved in 5mL dry DCM,
and then added drop-wise to stirring reaction via syringe. The reaction stirred at 0°
C for one hour, then allowed to warm up to room temperature and stirred overnight
(~20 hours). Contents were added to separatory funnel with ~25 mL DI water. After
removing the DCM, the aqueous layer was then washed twice with DCM. The
aqueous layer was placed under rotary evaporation to remove water. To rehydrate
film, 7mL nanopure water was added, and then moved to dialysis membrane. The
membrane was stirred in large beaker of nanopure water overnight (~20 hours) at
room temperature. The contents of the dialysis membrane were added to small
Falcon tubes and frozen under liquid nitrogen. The water was removed from the
product under a lyophilizer overnight (~18 hours).

2.2 Vesicle Preparation
2.2.1 Vesicles for DLS Studies
The general procedure for vesicle formation was consistent throughout all
the trials. However, there were certain variables that were altered from trial to trial
in order to optimize the vesicle formation. The general procedure started with
adding modified cyclodextrin, [2] or [3], to 25mL RBF, with guest molecule if
applicable, and dissolved in ~ 1mL chloroform, then placed under rotary
evaporation to remove all solvent and leave a thin film. The film was then hydrated
with 1 mL Tris buffer (10 mM, pH 7.4) for one hour. The vesicle formation
procedure was either by sonication or extrusion. Early samples were sonicated at
room temperature for one hour, then filtered through a 0.45 μm PTFE syringe filter.
21

Sample was then added to DLS cuvette and ~1 mL Tris buffer was added to
completely fill the cuvette. Samples that used extrusion as vesicle formation
procedure first employed freeze-thaw cycles to make vesicles at their lowest
energy state. Vesicle samples were frozen in dry ice in acetone and thawed in a
60° C water bath a total of 5 times. The sample was then filtered through a 0.45
μm PTFE syringe filter, then extruded through a 100 nm porous membrane a total
of 5 times (extruder pictured in Figure 11). Sample was then moved to a DLS
cuvette and ~1 mL Tris buffer added to completely fill the cuvette. Several variables
were tested in order to optimize the vesicle formation procedure to determine the
most efficient way. One such variable was dissolving the CD (and guest, if
applicable) in chloroform at an elevated temperature of 50° C versus room
temperature. Another variable explored was the film hydration temperature, either
50° C or room temperature. Finally, the ratio of guest to host equivalents was also
changed.

Figure 11. Extruder with membrane of pore size 100 nm used for vesicle isolation.
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2.2.2 Vesicles for Fluorescence Studies
To prepare fluorescent studies the same procedure was followed for the
vesicle preparation above using a CF buffer (10 mM CF, 10 mM Tris, pH 7.4). After
extrusion, the sample was passed through Sephadex gel permeation
chromatography in order to separate the dye-loaded vesicles from the free CF
molecules in buffer (Figure 12). The sample separated into three different colored
bands: brown, yellow and orange. The brown band was large aggregates of excess
Ad-PEG. The yellow band was determined to be the free CF dye in buffer, as the
dye is orange at self-quenching concentrations. Therefore, the orange band was
used for fluorescence studies, as the dye encapsulated by vesicles were at selfquenching concentrations.

Figure 12. Sephadex column separating particle sizes for fluorescence studies.
Excess Ad-PEG measures at 0-1.0 mL (brown), free CF dye at 1.0-1.6 mL (yellow),
and CF-containing vesicles at 1.6+ mL (orange).
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2.3 Fluorimeter Procedure
In glass cuvette, 2000 μL of Tris buffer solution and 25 μL of vesiclecontaining sample were added with stir bar. Cuvette was placed in fluorimeter and
the fluorescence was observed at λem 517 nm and λex 492 nm. The total run time
was 120 seconds, data taken at 0.1-second intervals. At t = 40 seconds, 20 μL of
Triton X was added to the cuvette to lyse the vesicles.

3. RESULTS AND DISCUSSION
3.1 Materials Synthesis
The main goal of this project was to synthesize a guest molecule that
contains a disulfide bond in order to form a nano-assembly that is degraded when
the redox sensitive disulfide bond is cleaved. The desired guest would contain an
adamantane one on end for inclusion into the CD and a PEG chain on the other to
provide a hydrophilic region to create an amphiphilic nano-assembly. The disulfide
bond would be in-between these two to form Ad-SS-PEG, as depicted in Scheme
1 below [7]. The process first couples a PEG chain to dithiodipropionoic acid,
which contains a disulfide bond between carboxylic acid end groups. Using
dicyclohexylcarbodiimide (DCC) and dimethylaminopyridine (DMAP) as coupling
agents, the alcohol of the PEG chain and the carboxylic acid interact in order to
tack the PEG chain on to the disulfide bond to create [6]. The second step of the
process uses the same coupling agents and adamantanol, to couple the
adamantane group to the other end of the disulfide bond.
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[7]

[6]

Scheme 1. Synthesis of guest molecule SS-PEG and Ad-SS-PEG.

Cleavage of this disulfide bond causes the guest molecule to degrade,
which in turn breaks apart the nanoparticle complex. The cleavage removes the
hydrophilic PEG chain from the guest molecule, and the remaining parts of the
assembly are not amphiphilic enough to maintain the bilayer structure. Breaking
apart the vesicle membrane releases the encapsulated cargo inside, thus
successfully delivering small molecules to a targeted location. The disulfide linkage
in the guest molecule is readily cleaved by glutathione (GSH), which is found in
higher concentration inside cells compared to extracellular environments. This
product is currently still a work in progress, as NMR results do not show the final
product and no vesicles were formed. Further work for this project should include
using other coupling agents to synthesize this product, as all attempts using DCC
have been unsuccessful.

Scheme 2. Synthesis of guest molecule Ad-PEG.

[5]

To determine optimal conditions in which to form vesicles, a different
adamantane guest molecule were first synthesized [5]. The initial guest contained
only adamantane attached to a PEG chain where n = 5, providing the hydrophilic
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portion in order to from an amphiphile when complexed with thioalkylated CD.
Adamantane derived guest molecule Ad-PEG synthesis, pictured in Scheme 2
above, was performed according to literature, which was simply heating all
reagents overnight (~18 hours) at 180° C.21 Initially, a heating mantel was used,
but the fluctuating heat was not steady enough for the reaction to run overnight,
and no product was formed. The second attempt was completed with a more stable
oil bath, which was successful and produced higher yield.
The synthesis of both bromocyclodextrin and the alkylthiol-modified CDs
followed procedures established in the lab, as seen in Scheme 3 below. While the
synthesis methods were reliable, several attempts at the modified CDs were
necessary before a high enough yield was collected. To create bromocyclodextrin,
bromine (Br2) and stock CD in the presence of triphenylphosphine were reacted
used to replace a hydroxyl group on the primary side of the CD with bromine to
create [1]. After several unsuccessful attempts at further modifying CDs to contain
a hydrophobic thioalkyl group, it was determined that the brominated CD needed
to be dried under high vacuum overnight (~12 hours) to remove all excess water,
as it was preventing the thioalkyl group from being able to bind to the CD. Once
the bromo-CD was dried, thioalkylated CDs were successfully synthesized ([2] and
[3]) under basic conditions in an SN2 reaction with [1]. All modified CDs were
isolated after synthesis by filtering through a frit and collecting the solid precipitate.
Products [2] and [3] were also dried under vacuum overnight to remove all excess
water to prevent interference in vesicle formation.

26

Scheme 3. Synthesis of first brominated cyclodextrin (center) and hydrophobecontaining cyclodextrin (right).

Products were confirmed by and compared to reported data in literature.
Figure 13 below depicts the NMR data for compound [2]. Important peaks are
labelled within the NMR spectrum to show that there are specific structures present
within the compound. The sugar protons are the bulk of the cyclodextrin. The SCH2- peak at 3.0 ppm shows that the thioalkyl is present, and that the hydrophobic
modification was successful. The one doublet for the H-1 proton indicates
complete and symmetrical substitution of the thioalkyl chain. If there were
substitutions on only 6 positions of the CD then there would be 7 different doublets
for the H-1 proton. The triplet at 2.8 ppm shows free thiol within the sample,
meaning stirring the compound in hot methanol did not remove all the unreacted
thiol from the product.
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Figure 13. Nuclear Magnetic Resonance for [2].

Figure 14 below depicts the NMR results for [1]. The peaks observed
corresponded with the peaks described in literature references, so [1] was used to
further synthesize CD with a hydrophobic thioalkyl chain, either [2] or [3].

Figure 14. Nuclear Magnetic Resonance for [1].
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The guest molecule Ad-PEG was also observed under NMR to determine
the success of the synthesis compared to literature. Figure 15 below shows the
results. The peaks match with the NMR results presented in the literature
references.

Figure 15. Nuclear Magnetic Resonance for [5].

3.2 Vesicle Preparation Optimization and Particle Size Distribution
The initial attempts to form vesicles closely followed the procedures outlined
previously reported, which was as follows: dissolving CD in chloroform and rotaryevaporating to create a thin film, then hydrating the film with Tris buffer for an hour
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and sonicating for an hour.17 Initial DLS measurements showed promising results,
so the same procedure was used to attempt CF dye encapsulation. Fluorimeter
results did not show any successful dye loading in vesicles, as addition of lysing
agent did not cause an increase in fluorescence which would indicate release of
trapped dye within the vesicles. Literature review revealed the wrong type of
particle size distribution was being observed. Using the correct style of distribution
curve, it was discovered that there were no particles present that fell within the
literature-accepted size range of vesicles. From there, several variables were
tested in order to successfully prepare vesicles.

Table 1 Vesicle Procedure Optimization
Trial

CD

Guest

Ratio

Isolation

Particle Radius (nm)

2

C12

Ad-TEG

1:1

Sonication

4 (62 %), 114 (11%), 711
(28%)

3

C12

Ad-PEG

1:1

Sonication

0.6 (97%)

4a

C12

Ad-PEG

1:1

Extrusion

2 (93%), 1306 (4%)

7

C12

Ad-PEG

1:1

Extrusion

3 (62%), 9188 (32%)

8

C12

Ad-PEG

2:1

Extrusion

3 (77%), 11 (8%), 260 (9%)

9b

C12

Ad-PEG

10:1

Extrusion

n/a

10

C12

Ad-PEG

5:1

Extrusion

9 (60%), 82 (29%), 317 (11%)

11c

C12

Ad-PEG

1:1

Extrusion

3 (85%), 23 (8%), 58 (4%)

12

C12

Ad-PEG

10:1

Extrusion

17(44%), 76 (56%)

14

C10

Ad-PEG

10:1

Extrusion

2 (98%)

Footnote: a: CD was dried under high vacuum to remove excess water. b: no
results available because solution was too chunky to finish extrusion. c: film
hydration heated to 50° C to improve solution viscosity.
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Table 1 above lists all the trials of vesicle preparation. The two methods of
sonication and extrusion were tested, as cited in literature.17 The first few trials
used modified CD that had not been completely dried under hi-vac. There was
excess water in the CD that interfered with the complete dissolution of product in
chloroform during film formation. After excess water was removed starting at trial
4 by placing CD under high vacuum overnight (~12 hours), the CD dissolved more
readily. The first few trials of using a guest molecule to help drive bilayer formation
used compound [4] as the guest. After unsuccessful formation, it was
hypothesized that the tetra(ethylene glycol) was too short. A major factor in selfassembly of amphiphiles in aqueous solution is the volume ratio between the
hydrophilic and hydrophobic regions of the amphiphilic. We hypothesized that the
tetra(ethylene glycol) hydrophilic chain was not long enough to achieve the need
balance for self-assembly into vesicles. To remedy this, a new adamantane
derivative was synthesized [5]. A PEG with an average molecular weight of 200
g/mol was used instead of the shorter TEG chain. Once a working Ad guest
molecule was discovered, the next variable to alter was the guest to host ratio. So
far, CD and Ad-PEG were added in molar equivalents. It was hypothesized that by
increasing the amount of guest molecule would increase the drive to vesicle
formation. Increasing to a ratio of 2:1 guest:host did not improve results, so the
ratio was increased to 10:1. This trial (9) was particularly difficult to perform due to
the high levels of Ad-PEG. The high viscosity of the guest molecule made filtering,
extruding, and separating incredibly difficult and slow, and no DLS results were
collected. The ratio was then reduced to 5:1, which was not only slightly easier to
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prepare than 10:1, but also showed more promising results than the 2:1. At this
point there was an idea to heat the film hydration process, starting with trial 11.
The RBF was placed in a 50° C oil bath while the buffer hydrated the film. This
made the rest of the vesicle formation process much easier, even the 10:1 ratio
trials. Another factor that improved the vesicle formation was using heat to help
dissolve the CD (and guest molecule, if applicable) in the chloroform before film
formation (see Trial 6). This helped create more evenly distributed films. Breaking
apart aggregates of CD improved the ability to properly form vesicles. One other
variable that was tested was completely drying the film under high vacuum after
rotary evaporation to remove all excess chloroform. This would prevent
interference of the chloroform during film hydration. No positive change was
observed in the DLS results after trying this, so drying the film under vacuum was
discontinued.
Table 2. Vesicle Preparation Negative Controls
Trial

CD

Guest

Ratio

Isolation

Particle Radius (nm)

1

C12

None

n/a

Sonication

4 (97%)

5

C10

None

n/a

Extrusion

0.6 (100%)

6

C12

None

n/a

Extrusion

2 (84%), 1603 (11%)

13

None

Ad-PEG

10:0

Extrusion

5 (36%), 133 (51%), 752 (11%)

17

C12

PEG

10:1

Extrusion

2 (99%)

Several negative controls were employed to ensure that positive results
were truly due to the controlled variables. Table 2 above summarizes the trials that
were used as negative controls. Trials 1, 5, and 6 show that a guest molecule is
needed in order to form vesicles, as modified CD does not form 3D complexes by
32

itself. Trial 13 shows that the guest molecule Ad-PEG does not form these
complexes by itself either. To determine the necessity of adamantane in forming
the inclusion complex, vesicles were attempted using C12 [2] and poly(ethylene
glycol) with an average molecular weight of 200 g/mol. This PEG is the same
compound used to synthesize the Ad-PEG guest [5] that successfully formed
vesicles. Using just PEG and modified CD, no vesicles were observed in DLS
measurements, proving the necessity of adamantane in forming guest-host
amphiphilic inclusion complexes.
The size and quantity of particles present in each sample of vesicle
preparation were observed via dynamic light scattering (DLS). Initially, the intensity
distribution was used to characterize the sample. Intensity distributions show the
percentages of each observed diameter in terms of how intense the reflected light
is.22 The larger particle sizes reflect more light than the smaller particles, and
therefore result in a much higher percentage. Even though there could be a smaller
population of these large particles, they still report a larger intensity distribution.
This was the incorrect type of distribution to observe because it does not accurately
portray the populations of each measured diameter. The first couple of vesicle
preparation methods were characterized using this type of distribution. This
mistake was realized when vesicle preparation procedures thought to have been
successful did not show signs of fluorescent dye encapsulation (further discussed
below in Section 3.3). Upon further literature review, it was determined that the
mass distribution was the accurate measurements to observe presence of vesicles
formed.17,20,22 The mass distribution displays the amount of each diameter
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category as a percentage of the total mass of particles observed. This is the correct
distribution to observe because the goal was to form a large population of vesicles
and separate out both aggregates and smaller free molecules. Ravoo reported
vesicles formed under sonication averaged 80-100 nm in diameter, while extruded
vesicles were larger, at 140-160 nm.17 These values were used to determine
whether vesicles were properly prepared.

Figure 16. Intensity Distribution of Unsuccessful Vesicles from Trial 1 using
undried C12 and Tris buffer.

Figure 17. Mass Distribution of Unsuccessful Vesicles from Trial 1 using undried
C12 and Tris buffer.
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Figure 16 and Figure 17 show the difference between the intensity and the
mass distributions of one of the initial vesicle preparation samples. The intensity
distribution shows a very higher percentage of particles at diameter 62.6 nm and
171.5 nm, which was initially taken to mean the majority of the particles present in
the sample were of those sizes. Upon reviewing literature, the mass intensity was
examined. Even though the intensity percentage was so high for diameters 62.6
nm and 171.5 nm, the mass percentage was zero, meaning no vesicles were
formed. Realization of this lead to further modifications of the vesicle preparation
methods.

Figure 18. Intensity Distribution of Successful Vesicles from Trial 12 using C12
and Ad-PEG in a 1:10 ratio.
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Figure 19. Mass Distribution of Successful Vesicles from Trial 12 using C12 and
Ad-PEG in a 1:10 ratio.

Figure 18 and Figure 19 displays the DLS measurements for successful
vesicle preparation. The intensity distribution (Figure 21) shows almost all of the
particles present in the sample had a diameter of 76.4 nm, similar to the intensity
distribution of unsuccessful vesicles. Looking at the mass distribution (Figure 22),
the percentage for the proper vesicle size range according to literature is
significantly higher than the samples from initial preparation methods. The mass
distribution shows that majority of the total mass (56.4%) was from particles of 76.4
nm, and less than half was from particles of 16.8 nm. It is likely that single-layered
micelles were formed in addition to the bilayer vesicles, which would be around the
size range of 17 nm in radius. The intensity distributions of the successful and the
unsuccessful vesicles both showed a high percentage for particles around 80 nm,
which is the correct size according to literature. However, the mass distribution
differences between the two trials show that almost no particles of the right vesicle
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size are present in Figure 20, while the successful vesicle trial in Figure 22 had a
much larger mass percentage, indicating the presence of vesicles.
DLS data was not available for vesicles prepared with the CF buffer due to
the fluorescent molecules. The fluorescence interrupted and interfered with the
lasers in the DLS instrument, so no accurate data on particle size distribution was
acquired.

3.3 Encapsulation
Based on promising DLS measurements, a vesicle preparation method was
executed using CF loaded dye in place of the Tris buffer to test for encapsulation.
If DLS showed particles falling within the range of reported vesicle size, the same
procedure was used to load vesicles with fluorescent dye. Carboxyfluorescein dye
was added to Tris buffer at self-quenching concentrations, so the molecules do not
fluoresce. CF is a bright orange powder and turns the buffer a bright orange as
well. Dilution of this buffer solution changed the color to a luminescent yellowgreen. The vesicle sample separated into two bands during the Sephadex column,
a bright yellow band and an orange band. This column separates large molecules
from small ones, specifically isolating dye-loaded vesicles from free CF in the
buffer solution. It was decided that the orange band contained the vesicles, as the
encapsulated dye was at self-quenching concentrations.
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Figure 20. Fluorimeter Results of Unsuccessful Encapsulation using the
procedure from Trial 1.

Figure 20 is a fluorimeter measurement of unsuccessful dye encapsulation
using the vesicle preparation procedure from Trial 1. The cuvette was equipped
with a stir bar and stirred throughout the duration of the experiment. The baseline
fluorescence measurement was established from t = 0 – 40s to account for any
free CF in the buffer or diffusion from the vesicle. At 40 seconds Triton X was
injected. To minimize light pollution as much as possible, a port with a small hole
just large enough for a pipette tip was constructed from black cardboard. A thick
piece of black cloth was used to cover the port hole until it was time to add the
Triton. While these measures helped reduce light pollution and noise in
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fluorescence measurements, completely eradicating background light was not
possible, and can be seen in measurements at the time when Triton was added.
The fluorescence experienced a sharp peak when the port cover allowed light into
the fluorimeter, but the fluorescence returned to the baseline once the cover was
replaced. This indicates the sample solution did not successfully encapsulate any
dye inside the vesicles. Addition of the lysing agent Triton X did not cause
degradation of vesicles, which would have released any trapped CF dye. The CF
dye present in the sample was already dilute enough to overcome self-quenching,
so it was at peak fluorescence before the addition of the lysing agent.

Figure 21. Fluorimeter Results for Successful Encapsulation using the procedure
from Trial 12.
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Figure 21 shows the change in fluorescence of a successful encapsulation from
using the procedure outlined in Trial 12. After addition of the lysing agent at 40
seconds, the fluorescence experiences a sharp peak and levels off at around
180000 CPS. Addition of Triton X causes the bilayer membrane to fall apart, thus
releasing the fluorescent cargo into the solution. The baseline fluorescence of
around 140000 CPS is the self-quenching emissions, and the increased
measurement of ~1.3 times the baseline is when the CF molecules are dilute
enough in solution to fluoresce freely. The sharp increase in fluorescence should
ideally be smooth, yet it has a lot of noise. This can be caused by light pollution as
the port cover is lifted to administer the Triton X. Overhead lights from the room
and natural light from the windows could have affected the fluorescence reading
while the lid was partially lifted to add the lysing agent to the sample. Several
attempts at smoothing the process were unsuccessful, and the rough spike in
measurements was present in all trials. This fluorescence study indicates that the
vesicle preparation procedure detailed in Trial 12 was truly successful in not only
vesicle formation, but that encapsulation was achieved as well with this procedure.
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Figure 22. Fluorimeter Data for C12 and Ad-PEG vesicles treated with GSH buffer
(t = 40s) and Triton X buffer (t = 80s).

Figure 22 above depicts the fluorimeters results from a trial of comparing
the lysing differences between GSH buffer and Triton X buffer. The vesicles were
composed of C12 and Ad-PEG, as outlined in Trial 12. This experiment was
performed to determine the effectiveness of GSH buffer on lysing vesicles that
have no disulfide bond. The GSH buffer was injected at t = 40 s, and it can be
observed that the fluorescence decreased from the baseline fluorescence. This
decrease in fluorescence shows that the glutathione has no effect on the stability
of the vesicles and does not cause degradation of the bilayer membrane. The
vesicles remain intact in the presence of GSH, and the sample only becomes
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diluted with the addition of the glutathione buffer. The concentration of GSH in the
buffer is in the range of intracellular concentrations (6 mM).18 This trial is to use as
a negative control to compare to vesicles made with Ad-SS-PEG to show that GSH
is necessary to break the disulfide bonds and cause degradation of the vesicle
membrane, releasing the entrapped cargo. From this trial, it is seen that GSH has
no effect on breaking vesicles that do not contain disulfide bonds. At t = 80 s, the
Triton X buffer was injected, to show that there were vesicles in the sample that
successfully encapsulated the CF dye. After the Triton X buffer was introduced,
the fluorescence of the sample increased from the diluted levels after GSH buffer
was added.

4. CONCLUDING REMARKS
While the ultimate goal of developing a supramolecular complex composed
of hydrophobic-modified cyclodextrin and an Ad-derived guest molecule containing
a cleavable disulfide bond was not achieved in this project, there were several
smaller successful steps that set a solid foundation for future progress. The
hydrophobic CDs were successfully synthesized, as seen in both the C10 and C12
compounds. An intermediate guest molecule, Ad-PEG, was also successfully
synthesized and used to determine the optimal vesicle formation procedure.
Encapsulation was also successfully proven by loading fluorescent dye into the
vesicles and lysing them to measure change in fluorescent intensity. Several
negative controls were used to show the credibility of the successful experiments.
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Modifying the CDs in a way that makes addition of a guest molecule
necessary for vesicle formation is important for future drug delivery applications.
The inability to prepare vesicles without the guest molecule is important for cargo
release purposes. Targeted delivery can be achieved by structuring the
degradation of the guest molecule under specific conditions that would cause the
vesicle to fall apart. Breaking apart the bilayer membrane then releases cargo.
Previous work has modified cyclodextrins to form vesicles from their own
hydrophobic and hydrophilic interactions, with no guest molecule needed.
There are several methods to continue on this project. The most important
one is to successfully synthesize the disulfide containing adamantane guest
molecule. A coupling agent other than DCC should be found, as all attempts using
it were unsuccessful. Another one is observing the cellular uptake of these
supramolecular nanoparticles. By using live cell cultures, transport of these
vesicles can be characterized and optimized. As the main purpose of creating
these vesicles is to deliver cargo into live cells, this future direction would
determine the overall success of the project. Another possibility is the use of
scanning electron microscopy and/or transmission electron microscopy to view the
guest-host complexes. Visual characterization of the vesicles could provide
important data on how well the guest molecules are included into the hydrophobic
regions of the CDs. Use of a confocal microscope can provide important
characterization of the diffusion properties. This is important to be able to predict
accurate dosing and time-release of the encapsulated cargo. Drug-loaded vesicles
can be used in several administrative routes, such as orally, parenteral injections,
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or transdermally. Being able to observe the diffusion characteristics through
Brownian motion could be used to predict the behavior of these vesicles under real
physiological settings. Since successful encapsulation of hydrophilic molecules
was achieved, it would be interesting to attempt encapsulation of hydrophobic
molecules. A large majority of pharmaceutical products are hydrophobic, so being
able to load them into the membrane of these vesicles could potentially improve
bioavailability of these drugs.
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